This HTML5 document contains 143 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q47271726
rdf:type
wikibase:Item
schema:description
2004년 논문 article científic wetenschappelijk artikel наукова стаття, опублікована в липні 2004 2004年学术文章 სამეცნიერო სტატია জুলাই ২০০৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ videnskabelig artikel articolo scientifico artículo científico publicado en 2004 artikulong pang-agham научни чланак 2004年學術文章 scientific article published in July 2004 2004年学术文章 vitskapeleg artikkel 2004年学术文章 2004年學術文章 tieteellinen artikkeli 2004年学术文章 artículu científicu scienca artikolo bilimsel makale artigo científico 2004年學術文章 научная статья επιστημονικό άρθρο vitenskapelig artikkel 2004年の論文 naučni članak artykuł naukowy vedecký článok artikull shkencor scientific article published in July 2004 2004年學術文章 مقالة علمية نشرت في يوليو 2004 мақолаи илмӣ teaduslik artikkel article scientifique articol științific artigo científico מאמר מדעי 2004年学术文章 bài báo khoa học artigo científico научна статия научни чланак vědecký článek 2004 nî lūn-bûn article scientific tudományos cikk บทความทางวิทยาศาสตร์ scientific article published in July 2004 vetenskaplig artikel 2004年學術文章 artikel ilmiah wissenschaftlicher Artikel 2004年学术文章
p:P577
wds:Q47271726-19A5B2E2-B6B6-4D8A-B769-094712A0061B
wdt:P577
2004-07-01T00:00:00Z
p:P407
wds:Q47271726-8B36897A-2702-48B9-AB51-FBDF9678C601
wdt:P407
wd:Q1860
p:P2860
wds:Q47271726-FAEB3B1B-5351-4453-B51D-1D129481A360 wds:Q47271726-FF1553E4-3485-46D7-A578-97D2A7F9846C wds:Q47271726-EFD78ED7-8DBB-48F9-B4C4-D47A614EC15D wds:Q47271726-5FD628DB-95CC-4978-B586-D9CA424ABB80 wds:Q47271726-6345D51A-92D3-4D47-9C93-BFCB31A6FA9B wds:Q47271726-2BA15E93-5A71-41DB-B511-2F19EBDAEA35 wds:Q47271726-34F0FDC8-F9E7-4A3B-846B-A3780924C81D wds:Q47271726-003085F6-A806-4A90-8872-A822E3BCB9C0 wds:Q47271726-02621E6C-5E05-4DB1-9868-F4DBBFDD77B5 wds:Q47271726-0E8E3839-33DB-4AC2-9AE2-456F1D230E79 wds:Q47271726-DBB87639-E2B6-48E9-8CCA-24EF4FD2F481 wds:Q47271726-CADCC122-04A3-46A0-B32F-C0A1B1EB9B7A wds:Q47271726-81DDA9EE-F065-4567-9B62-67057C5022ED wds:Q47271726-85A987F4-C520-43F0-B369-3FD7261C8B35 wds:Q47271726-93298E5A-A0F7-4E05-BEA0-CB2B6E1FE9BC wds:Q47271726-73F4EF12-4A99-40E9-9F46-E969E97A27A4 wds:Q47271726-8015B7C7-A03E-4D94-8FFB-2EED1AC4A4C4
wdt:P2860
wd:Q44387824 wd:Q57265459 wd:Q28202251 wd:Q72462916 wd:Q48362690 wd:Q40433213 wd:Q72722530 wd:Q28202504 wd:Q57569294 wd:Q43831403 wd:Q47784405 wd:Q77341367 wd:Q29620713 wd:Q68350435 wd:Q33867651 wd:Q67512879 wd:Q34060890
p:P2093
wds:Q47271726-E3A503DC-59CC-4CCC-B6E0-83D1670ED67F wds:Q47271726-7D17DC6F-A29F-4C74-B24F-AC0A71C758D2 wds:Q47271726-6EE3F54F-4878-4B2E-82A1-C92A63EA6EA6 wds:Q47271726-40A8F415-77D8-4580-B762-C4F4CF76C8B4 wds:Q47271726-68674AD3-1750-4B36-8AC4-F27C407E712D wds:Q47271726-F3010774-0A09-4B4C-8278-3D63D12D47AD wds:Q47271726-EA905DEF-5E65-4BBF-96E5-0FA4ABAC1B21
wdt:P2093
Allan Olson Carrie L Wagner Mohan Bala Lloyd Mayer Suzanne Travers Robert H Diamond Warren Bao
rdfs:label
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
skos:prefLabel
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
schema:name
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
p:P50
wds:Q47271726-502C801D-750B-4E2C-95C5-BC324500E004 wds:Q47271726-59C17B75-61CD-4286-BC6C-647CF4D8ABA9
wdt:P50
wd:Q87669570 wd:Q30247987
p:P1476
wds:Q47271726-A3F5333A-30E9-499E-AE06-8E53ABA2AC91
wdt:P1476
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
p:P304
wds:Q47271726-115F2906-F1AF-40ED-8926-9DECC5964F59
wdt:P304
542-553
p:P31
wds:Q47271726-D8FA3428-0C1C-44DA-8108-BADC7863227B
wdt:P31
wd:Q13442814
p:P921
wds:Q47271726-AF1FCE22-AF0B-415C-B506-9076BA3A697D wds:Q47271726-D2038E6E-E50A-4FB0-A56B-BBC416E53D30
wdt:P921
wd:Q1472 wd:Q79460
p:P698
wds:Q47271726-4F5E270F-5874-4255-9687-05FB8E228B19
wdtn:P698
n10:15224278
wdt:P698
15224278
p:P1433
wds:Q47271726-F572295F-7A00-4EC7-9691-A53187D01E9B
wdt:P1433
wd:Q5133759
p:P433
wds:Q47271726-40D81EFE-53F4-4983-A567-B00892145B5A
p:P478
wds:Q47271726-E3465227-3373-45B1-A5DA-7D3555DB4E7A
wdt:P433
7
wdt:P478
2
p:P356
wds:Q47271726-06613A48-9984-412F-9A49-5EBA97983083
wdtn:P356
n12:S1542-3565(04)00238-1
wdt:P356
10.1016/S1542-3565(04)00238-1